文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.

作者信息

Zhao Huajun, Shao Xianyu, Yu Yating, Huang Lulu, Amor Narh Philip, Guo Kun, Weng Changzhen, Zhao Weijun, Yang Ailu, Hu Jiesen, Yang Hongbao, Liu Zhenguang, Han Qiuju, Shi Leilei, Sun Shiyu, Zhang Jian, Lin Ang, Yang Yong

机构信息

Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.

Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

出版信息

NPJ Vaccines. 2024 Feb 3;9(1):22. doi: 10.1038/s41541-024-00813-3.

DOI:10.1038/s41541-024-00813-3
PMID:38310094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10838333/
Abstract

Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/495f585a5934/41541_2024_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/495f585a5934/41541_2024_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg

相似文献

[1]
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.

NPJ Vaccines. 2024-2-3

[2]
The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model.

Virol J. 2017-10-25

[3]
The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.

Virol J. 2018-5-21

[4]
HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice.

J Biomed Sci. 2020-5-28

[5]
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.

JHEP Rep. 2022-10-13

[6]
A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.

J Virol. 2019-2-19

[7]
A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA.

Cell Mol Gastroenterol Hepatol. 2022

[8]
Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.

J Virol. 2014-9

[9]
Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.

J Hepatol. 2023-4

[10]
Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B.

Virol J. 2013-6-28

引用本文的文献

[1]
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.

Virol J. 2025-8-11

[2]
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies.

Hepatol Int. 2025-6-11

[3]
Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.

Biol Proced Online. 2025-6-3

[4]
Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy.

Vaccines (Basel). 2025-4-24

[5]
Viral oncogenesis in cancer: from mechanisms to therapeutics.

Signal Transduct Target Ther. 2025-5-12

[6]
A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane.

Pharmaceutics. 2025-2-7

[7]
Current and emerging strategies for the prevention of hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol. 2025-3

[8]
mRNA vaccines for infectious diseases - advances, challenges and opportunities.

Nat Rev Drug Discov. 2024-11

[9]
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.

Biomark Res. 2024-8-31

[10]
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems.

Vaccines (Basel). 2024-8-1

本文引用的文献

[1]
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.

Nat Commun. 2023-6-19

[2]
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.

Nature. 2023-6

[3]
Algorithm for optimized mRNA design improves stability and immunogenicity.

Nature. 2023-9

[4]
Discovery of a first-in-class orally available HBV cccDNA inhibitor.

J Hepatol. 2023-4

[5]
Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction.

Cell Mol Immunol. 2022-12

[6]
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.

Gut. 2023-8

[7]
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine.

Nat Immunol. 2022-4

[8]
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.

Signal Transduct Target Ther. 2021-5-31

[9]
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.

Lancet Infect Dis. 2021-9

[10]
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Hum Vaccin Immunother. 2021-5-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索